Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial

An ongoing randomized, double-blind, controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of a mosaic-type recombinant vaccine candidate, named NVSI-06-09, as a booster dose in subjects aged 18 years and older from the United Arab Emirates (UAE), who had administered two...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaabi, Nawal Al, Yang, Yun Kai, Liang, Yu, Xu, Ke, Zhang, Xue Feng, Kang, Yun, Jin, Yu Qin, Hou, Jun Wei, Zhang, Jing, Yang, Tian, Hussein, Salah, ElDein, Mohamed Saif, Lei, Ze Hua, Zhang, Hao, Shao, Shuai, Liu, Zhao Ming, Liu, Ning, Zheng, Xiang, Su, Ji Guo, Yang, Sen Sen, Cong, Xiangfeng, Tan, Yao, Lei, Wenwen, Gao, Xue Jun, Jiang, Zhiwei, Wang, Hui, Li, Meng, Mekki, Hanadi Mekki, Zaher, Walid, Mahmoud, Sally, Zhang, Xue, Qu, Chang, Liu, Dan Ying, Yang, Mengjie, Eltantawy, Islam, Xiao, Peng, Shen, Fu Jie, Wu, Jin Juan, Han, Zi Bo, Du, Li Fang, Tang, Fang, Chen, Shi, Ma, Zhi Jing, Zheng, Fan, Hou, Ya Nan, Li, Xin Yu, Li, Xin, Wang, Zhao Nian, Yin, Jin Liang, Mao, Xiao Yan, Zhang, Jin, Qu, Liang, Zhang, Yun Tao, Yang, Xiao Ming, Wu, Guizhen, Li, Qi Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808735/
https://www.ncbi.nlm.nih.gov/pubmed/36596779
http://dx.doi.org/10.1038/s41392-022-01295-2

Ejemplares similares

Ejemplares similares